Polaris AI Pharma폴라리스AI파마
041910 · KOSDAQ · ₩041910 · 폴라리스AI파마
- Market cap
- ₩74B
- Enterprise value
- ₩72B
- P/E
- 6.4×
- P/B
- 0.5×
- Dividend yield
- 0.0%
- ROE
- 7.9%
- Net margin
- 20.2%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−45.4% from the high
₩4,110Today: ₩5,460 – ₩5,790₩10,200
Returns
- 1W−2.3%
- 1M+3.3%
- 3M+4.5%
- 6M−20.0%
- YTD−10.6%
- 1Y−12.8%
- Volume today
- 50,723
- 1.3× the 20-day average
- Traded today
- ₩283M
- Listed shares
- 13,283,350
- EPS (12 months)
- ₩874
- Earnings yield 15.7%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Normal- BuzzNormalBuzz 49 of 100 (50 is a normal day for this stock).
- MomentumFlat3.7% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Polaris AI Pharma stock overview
Polaris AI Pharma (폴라리스AI파마, KRX: 041910) is listed on KOSDAQ, in the Biotech & Pharma sector. The company operates in three business segments: API (active pharmaceutical ingredients, including generic drugs and new and improved drug ingredients), CDMO (contract development and manufacturing of drugs, including custom pharmaceutical ingredients and formulation development and production), and other businesses. Its shares closed at ₩5,570 on Oct 26, 2026, down 1.94% on the day, giving it a market value of ₩74B.
Key facts
- Market cap
- ₩74B
- Sector
- Biotech & Pharma
- Latest price change
- −1.94%
- As of
- Oct 26, 2026
- Main business
- The company operates in three business segments: API (active pharmaceutical ingredients, including generic drugs and new and improved drug ingredients), CDMO (contract development and manufacturing of drugs, including custom pharmaceutical ingredients and formulation development and production), and other businesses.
Quick answers about Polaris AI Pharma
- What does Polaris AI Pharma do?
- The company operates in three business segments: API (active pharmaceutical ingredients, including generic drugs and new and improved drug ingredients), CDMO (contract development and manufacturing of drugs, including custom pharmaceutical ingredients and formulation development and production), and other businesses. Its main customers are finished-drug pharmaceutical companies, with more than 100 customers in Korea and abroad, and it exports mainly to Japan. Its main manufacturing facility is located in Hwaseong, Gyeonggi-do.
- What is the market cap of Polaris AI Pharma?
- The market capitalisation of Polaris AI Pharma was ₩74B at the close on Oct 26, 2026.
- Who are the largest shareholders of Polaris AI Pharma?
- According to the latest official filings, the largest reported holders are Polaris Office (32.97%, as of Jul 24, 2026).
- When is the next earnings report from Polaris AI Pharma?
- Korean companies rarely announce results dates in advance. Based on when Polaris AI Pharma filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Company profile
The company operates in three business segments: API (active pharmaceutical ingredients, including generic drugs and new and improved drug ingredients), CDMO (contract development and manufacturing of drugs, including custom pharmaceutical ingredients and formulation development and production), and other businesses. Its main customers are finished-drug pharmaceutical companies, with more than 100 customers in Korea and abroad, and it exports mainly to Japan. Its main manufacturing facility is located in Hwaseong, Gyeonggi-do.
Written by AI from the company's latest annual report.
- Korean name
- 폴라리스AI파마
- Sector
- Biotech & Pharma
- CEO
- 조원경, 이성엽
- Founded
- Dec 1998
- Listed
- Feb 2004
- Listed shares
- 13,283,350
- Fiscal year ends
- Month 12
- Website
- www.polarisaipharma.com
Similar companies
- Samsung Biologics207940 · ₩67T₩1,452,000−0.95%
- Celltrion068270 · ₩44T₩190,000−2.26%
- Alteogen196170 · ₩15T₩218,500−2.67%
- Yuhan000100 · ₩6T₩81,700−3.54%
- SK biopharmaceuticals326030 · ₩5.9T₩75,800−1.43%
- HLB028300 · ₩5.2T₩39,250−5.65%
- Hanmi Pharm128940 · ₩4.5T₩352,500−2.49%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,900−5.17%
Recent filings
See all- Half-year report (Jun 2026)Aug 14, 2026
- Adjustment of Conversion PriceJul 27, 2026
- 5%+ holding reportJul 24, 2026
- 5%+ holding reportJul 10, 2026
- Quarterly report (Mar 2026)May 15, 2026
Titles in Korean until English translations are added.
Also known as: Polaris AI Pharma / 폴라리스AI파마 / 041910 / KRX:041910
Source: KRX statistical information